Bahl & Gaynor Inc. cut its holdings in Mesa Laboratories, Inc. (NASDAQ:MLAB) by 10.7% in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,785 shares of the medical instruments supplier’s stock after selling 1,050 shares during the quarter. Bahl & Gaynor Inc. owned 0.23% of Mesa Laboratories worth $1,078,000 at the end of the most recent quarter.

Other hedge funds have also bought and sold shares of the company. Kayne Anderson Rudnick Investment Management LLC grew its holdings in shares of Mesa Laboratories by 4.5% in the second quarter. Kayne Anderson Rudnick Investment Management LLC now owns 70,189 shares of the medical instruments supplier’s stock valued at $10,059,000 after purchasing an additional 3,001 shares in the last quarter. Spark Investment Management LLC purchased a new position in shares of Mesa Laboratories in the second quarter valued at $300,000. Thomson Horstmann & Bryant Inc. grew its holdings in shares of Mesa Laboratories by 75.4% in the second quarter. Thomson Horstmann & Bryant Inc. now owns 72,362 shares of the medical instruments supplier’s stock valued at $10,370,000 after purchasing an additional 31,107 shares in the last quarter. Royce & Associates LP grew its holdings in shares of Mesa Laboratories by 56.8% in the second quarter. Royce & Associates LP now owns 78,530 shares of the medical instruments supplier’s stock valued at $11,254,000 after purchasing an additional 28,458 shares in the last quarter. Finally, Eqis Capital Management Inc. grew its holdings in shares of Mesa Laboratories by 5.6% in the second quarter. Eqis Capital Management Inc. now owns 5,188 shares of the medical instruments supplier’s stock valued at $744,000 after purchasing an additional 273 shares in the last quarter. 67.20% of the stock is owned by hedge funds and other institutional investors.

In related news, Director H Stuart Campbell sold 1,000 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $143.09, for a total transaction of $143,090.00. Following the completion of the sale, the director now directly owns 47,976 shares in the company, valued at $6,864,885.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have sold 8,610 shares of company stock valued at $1,176,809 over the last quarter. 17.00% of the stock is owned by company insiders.

A number of research analysts recently weighed in on the stock. TheStreet lowered shares of Mesa Laboratories from a “b” rating to a “c+” rating in a report on Monday, July 31st. Zacks Investment Research raised shares of Mesa Laboratories from a “hold” rating to a “buy” rating and set a $159.00 target price for the company in a report on Tuesday, June 13th. Finally, BidaskClub lowered shares of Mesa Laboratories from a “sell” rating to a “strong sell” rating in a report on Saturday, August 12th.

WARNING: This article was first posted by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was illegally copied and reposted in violation of U.S. & international copyright and trademark laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/17/mesa-laboratories-inc-mlab-shares-sold-by-bahl-gaynor-inc.html.

Mesa Laboratories, Inc. (MLAB) opened at 146.68 on Friday. Mesa Laboratories, Inc. has a 12-month low of $109.14 and a 12-month high of $169.81. The company has a 50 day moving average of $136.39 and a 200-day moving average of $138.07. The stock has a market capitalization of $551.22 million, a price-to-earnings ratio of 52.72 and a beta of 0.47.

Mesa Laboratories (NASDAQ:MLAB) last issued its quarterly earnings results on Monday, July 31st. The medical instruments supplier reported $0.39 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.56 by ($0.17). Mesa Laboratories had a return on equity of 16.58% and a net margin of 11.31%. The firm had revenue of $22.67 million for the quarter, compared to analysts’ expectations of $22.90 million. On average, equities research analysts forecast that Mesa Laboratories, Inc. will post $2.72 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Thursday, August 31st were given a dividend of $0.16 per share. This represents a $0.64 annualized dividend and a dividend yield of 0.44%. The ex-dividend date was Tuesday, August 29th. Mesa Laboratories’s payout ratio is 22.94%.

Mesa Laboratories Profile

Mesa Laboratories, Inc is focused primarily on quality control products and services. The Company operates through four segments: Instruments, Continuous Monitoring, Biological Indicators and Cold Chain. The Instruments Division designs, manufactures and markets quality control instruments and disposable products.

Institutional Ownership by Quarter for Mesa Laboratories (NASDAQ:MLAB)

Receive News & Ratings for Mesa Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.